布吉他滨Alunbrig(brigatinib)

[Description of Alunbrig(Brigatinib) on the guitar]

On April 28th, 2017, FDA approved it for patients with anaplasticlymphomakinase’s disease (ALK)- metastatic non-small cell lung cancer (NSCLC) or intolerance to crizotinib.

Buguita Binalun Brig (Brigatinib) _ Hong Kong Jimin Pharmaceutical

Bujitabine Alunbrig(Brigatinib) is a tyrosine kinase inhibitor. Its in vitro activity and clinically achievable concentration can inhibit a variety of kinases including ALK, ROS1, insulin-like growth factor -1 receptor (IGF-1R), FLT-3, EGFR deletion and point mutation.

Albumin brig (brigatinib) can inhibit ALK autophosphorylation and ALK- mediated phosphorylation of downstream signal proteins STAT3, AKT, ERK1/2, and S6 in vitro and in vivo. Brigatinib can also inhibit the proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins in vitro, and show an inhibitory effect on xenograft growth dose-dependent EML4-ALK- positive non-small cell lung cancer (NSCLC).

[Alunbrig(Brigatinib) specification for guitar]

This product is packed in tablets, 30mg/180 tablets.

[Usage and dosage of Alunbrig(Brigatinib) on guitar]

This product needs to be taken orally, once a day, 90mg； each time; If drug resistance occurs, it can be increased to 180mg, and the maximum can not exceed 180mg per day. Can be taken before/after meals.

[Clinical and data of Alunbrig(Brigatinib) on Buguitar]

At the clinically achievable concentration (≤ 500 nM), Brigatinib can inhibit the variability of cells expressing EML4-ALK in vitro and para-ALK inhibitors related to the formation of 17 mutants (including Crizotinib, EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT). Brigatinib showed antitumor activity in vivo against four mutant forms of EML4-ALK, including G1202R and L1196M mutants which have been identified in NSCLC which has been developed with Crizotinib. Brigatinib can also reduce the tumor load and prolong the life of mice implanted with an ALK-driven tumor cell line.